Acetohexamide

CHEMBL1589 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
324.4 g/mol
LogP
2.4
Phase
4

An older oral diabetes medication belonging to the sulfonylurea class that stimulates the pancreas to release more insulin after meals. It was used to lower blood glucose in people with type 2 diabetes whose pancreas still produces some insulin. It has largely been replaced by newer sulfonylureas and other diabetes medications with more favorable safety profiles and less risk of prolonged low blood sugar.

น้ำหนักโมเลกุล

324.4000 g/mol

LogP

2.40

TPSA

101.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)c1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1

InChI

InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)

Molecular Formula

C15H20N2O4S

HBD / HBA

2 / 4

พันธะที่หมุนได้

4

อะตอมหนัก

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An older oral diabetes medication belonging to the sulfonylurea class that stimulates the pancreas to release more insulin after meals. It was used to lower blood glucose in people with type 2 diabetes whose pancreas still produces some insulin. It has largely been replaced by newer sulfonylureas and other diabetes medications with more favorable safety profiles and less risk of prolonged low blood sugar.

Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

Yes, Acetohexamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1589. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 1989. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.